Adam Lambert

Director, Marketing, EEMEA 


Tell us about your organisation and its journey to date.

Since it was founded in 1888, Abbott has been playing a leading role in shaping the future of healthcare. With our large portfolio of life-changing technologies in diagnostics, medical devices, nutritionals and generic pharmaceuticals, we have been helping people unlock their full potential and live healthier at all stages of life. Two billion people around the world are touched by our science-based products and solutions, and we aim at reaching 3 billion people by 2030.   

How has the organisation evolved to address the challenges of an ever-changing healthcare sector? Please list some accomplishments.

Throughout its journey, Abbott has been at the forefront of multiple healthcare challenges which the world has witnessed thus far. In 1985, we developed the first licensed HIV test to help secure the safety of blood supply. Recently, Abbott has been at the forefront of the battle against COVID-19; our scientists and engineers worked around the clock to develop 12 different tests spanning molecular, antibody and rapid antigen tests to help curb the spread of the disease and enable nations and economies to resume normality. Our innovative continuous glucose monitoring system FreeStyle Libre has been relieving people with diabetes from the pain of fingersticks and helping them better manage their diabetes and achieving better health outcomes.

Tell us about your presence in the Middle East.

Abbott has been proudly serving the Middle East for more than 75 years. Not only is the Middle East an important market for Abbott, but we have also been a trusted partner to the region’s governments and the healthcare sector. Many of our innovative products make their debut in the Middle East, and we are constantly working to increase our contribution to elevate healthcare standards and improve services to meet people’s needs and expectations.

What will your presence look like at Medlab Middle East 2023?

Medlab Middle East has carved for itself a prominent ranking amongst global healthcare exhibitions. Over the last few years, Abbott has been actively present as the main sponsor of Medlab Middle East, and we are doubling our footprint in 2023 to present a larger number of innovative products and solutions, including those aimed at addressing current and future healthcare challenges. 

What do you believe those imminent health challenges are and what will you be showcasing at Medlab Middle East in 2023?

As it is largely believed now, COVID is far from being behind us, and the flu season has also been quite severe across the region. This, together with RSV, has burdened the healthcare sector. Therefore, adequate testing can play a pivotal role in reducing the spread of diseases and protecting people, especially those at high risk.

That said, we will be showcasing several innovative products that have been playing a major role in fighting the COVID-19 pandemic and the flu seasonal endemic. Among those are Abbott’s ID NOW™ molecular point-of-care rapid test, which uses molecular isothermal technology to detect a number of viruses, including COVID-19 and Influenza.

We will also present Panbio™ COVID-19 Antigen Self-Test and Panbio COVID-19/Flu A&B Rapid Panel, in addition to several other infectious diseases tests, such as NxTek (malaria) and Panbio™ HIV self-test.